Sarepta Therapeutics
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
公司地址 215 First Street, Suite 415, Cambridge, MA, USA, 02142
電話號碼 +1 617 274-4000
傳真號碼 +1 800 621-5203
公司網頁 https://www.sarepta.com
員工數量 835
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Louise Rodino-Klapac, PhD President, Research and Development and Technical Operations 美元 752.51K 24/04/2026
Mr. Ian Michael Estepan President and Chief Operating Officer 美元 740.53K 24/04/2026
Mr. Ryan H. Wong Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 480.12K 24/04/2026
Ms. Cristin L. Rothfuss Executive Vice President, Chief General Counsel and Corporate Secretary 美元 629.86K 24/04/2026
Mr. Douglas S. Ingram,Esq. Director and Chief Executive Officer 美元 1.17M 25/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Michael A. Chambers Independent Director 24/04/2026
Dr. Stephen L. Mayo, PhD Independent Director 24/04/2026
Dr. Kathryn Jean Boor, PhD Independent Director 24/04/2026
Mr. Richard J. Barry Independent Director 24/04/2026
Dr. Hans Wigzell, M.D.,PhD Independent Director 24/04/2026
Dr. Claude Nicaise,M.D. Independent Director 24/04/2026
Mr. Douglas S. Ingram,Esq. Director and Chief Executive Officer 25/02/2026
Ms. Deirdre P. Connelly Independent Director 24/04/2026
Dr. M. Kathleen Behrens Wilsey, PhD Chairwoman of the Board 24/04/2026
 
所屬ETF (更新日期: 02/05/2026 04:23)
代號 名稱 佔比% ▼ 持有日期
AVKAdvent Convertible & Income Fund<0.000001%31/07/2025
AVLCAvantis U.S. Large Cap Equity ETF<0.000001%18/09/2025
BALIiShares U.S. Large Cap Prm Inc Act ETF<0.000001%01/08/2025
BBHVanEck Biotech ETF<0.000001%23/09/2025
BBMCJPMorgan BetaBuilders US Mid Cap Eq ETF<0.000001%22/12/2025
BIBLInspire 100 ETF<0.000001%01/10/2025
BKMCBNY Mellon US Mid Cap Core Equity ETF<0.000001%07/08/2025
BLESInspire Global Hope ETF<0.000001%02/01/2026
BMEDiShares Health Innovation Active ETF<0.000001%26/02/2026
BMEZBlackRock Health Sciences Term Trust<0.000001%31/12/2025
BTALAGF U.S. Market Neutral Anti-Beta<0.000001%01/12/2025
DFACDimensional US Core Equity 2 ETF<0.000001%14/08/2025
DFATDimensional US Targeted Value ETF<0.000001%17/09/2025
DFAUDimensional US Core Equity Market ETF<0.000001%23/04/2026
DFUSDimensional US Equity Market ETF<0.000001%22/04/2026
EZMWisdomTree U.S. MidCap Earnings ETF<0.000001%11/12/2025
FLCCFederated Hermes MDT Large Cap Core ETF<0.000001%15/08/2025
FNYFirst Trust Mid Cap Growth AlphaDEX® ETF<0.000001%07/10/2025
FRTYAlger Mid Cap 40 ETF<0.000001%25/08/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%15/08/2025
  1    2    3    4    5   6    7    8    9  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.